• Efficacy and safety of three antiretroviral therapy regimens (DTG v EFV) started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial - (06/19/23)
   
  
• NIH OAR Aging/HIV Virtual Meeting: HIV and Aging Research: Current Landscape and Opportunities, Sept 5 2023 - (09/24/23)
   
  
• Pitavastatin to Prevent Cardiovascular Disease in HIV Infection - (09/24/23)
   
  
• EUROPEAN COMMISSION AUTHORISES ViiV HEALTHCARE'S APRETUDE (CABOTEGRAVIR LONG-ACTING AND TABLETS) FOR HIV PREVENTION - (09/19/23)
   
  
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults; HIV Pipeline: GSK/ViiV, Gilead, Merck - (09/19/23)
   
  
• A formula for the end [of HIV], Paradigm Shift by Pharma - (09/19/23)
   
  
• Abbvie ABBV-382+ Budigalimab with ATI in PWH - (09/19/23)
   
  
• Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study - (09/19/23)
   
  
• bNAb+Cabotegravir v SOC Phase 2b - (09/15/23)
   
  
• CROI: N6LS WITH RHUPH20 ENABLES SAFE HIGH DOSE MONOCLONAL ANTIBODY SUBCUTANEOUS DELIVERY - (09/15/23)
   
  
• CROI: Impact of Baseline Factors on Virologic Response to bNAb VH3810109 (N6LS) in BANNER - (09/15/23)
   
  
• Aging Begins at Time of HIV Infection, Frailty in PWH - (09/13/23)
   
  
More HIV Articles...
 

• HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
   
  
• IAS: Hepatitis delta and liver disease among people living with hepatitis B in Senegal - (08/14/23)
   
  
• EASL: Estimating the Prevalence of Hepatitis Delta Infection among Foreign-Born Adults with Chronic Hepatitis B in the United States - (07/05/23)
   
  
• EASL: Impact of the anti-HDV reflex testing on the reduction of hepatitis D burden in Spain - (07/05/23)
   
  
• EASL: Low coverage of hepatitis D virus testing in individuals with HIV and HBV in the Netherlands (ATHENA): a retrospective, cross-sectional and longitudinal study - (07/05/23)
   
  
• EASL: Prevalence (15%) and incidence of delta hepatitis in HIV-HBV coinfected patients in the Dat'AIDS (French) cohort - (07/05/23)
   
  
• EASL: An international coalition to eliminate hepatitis B virus (ICE-HBV) survey confirms inadequate HBV/HDV screening and diagnosis diminishing elimination targets in resource limited settings - (07/05/23)
   
  
• EASL: Off-label Bulevirtide monotherapy for chronic hepatitis D virus infection in patients with decompensated liver disease - (07/05/23)
   
  
• EASL: Five years follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D - (07/05/23)
   
  
More Hep D Articles...
 


---


 
Aging & Perinatally HIV Infected
 

• NIH OAR Aging/HIV Virtual Meeting: HIV and Aging Research: Current Landscape and Opportunities, Sept 5 2023 - (09/24/23)
   
  
• Pitavastatin to Prevent Cardiovascular Disease in HIV Infection - (09/24/23)
   
  
• Reversal of epigenetic aging and immunosenescent trends in humans - (09/19/23)
   
  
• FDA: Colchicine (marketed as Colcrys) Information - (08/27/23)
   
  
• Colchicine in Patients with Chronic Coronary Disease - (08/27/23)
   
  
• FDA Product Insert LODOCO (colchicine) tablets, for oral use - (08/27/23)
   
  
• IAS: Fostering cognitive and mental health in people aging and living with HIV while prioritizing the community and lived experience perspectives - (08/18/23)
   
  
More Aging & HIV Articles...
 


---


 
Mpox
 

• IAS: People living with HIV not more likely to be hospitalized with mpox unless immunosuppressed, finds WHO analysis - (07/25/23)
   
  
More Monkeypox Articles...
 

• The national hepatitis C elimination program-AASLD's coalition and call to action - (09/24/23)
   
  
• A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study - (09/24/23)
   
  
• Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C - ongoing - (09/22/23)
   
  
• The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination - (09/22/23)
   
  
• Reinfection incidence and risk among people treated for recent hepatitis C virus infection - (09/12/23)
   
  
• Mavyret + Sofosbuvir (RBV) for Sof/Vel/Vox Failures - (08/27/23)
   
  
• New CDC HCV Acute, Chronic & Deaths in USA: doubled acute cases; death rates highest among 55-74 year-olds - (08/19/23)
   
  
• Hepatitis C Treatment Initiation Among US Medicaid Enrollees - (08/09/23)
   
  
• High Mortality despite SVR Cure Due to Lack of Surveillance & Continued Drug/Alcohol Use - (08/09/23)
   
  
• HCV DAA Costs & Use Gilead Millman Report - (08/09/23)
   
  
• IAS: Integrating hepatitis C services into ART clinics in low and middle income countries (LMICs) as an approach toward hepatitis C micro-elimination: pilot experience in Nigeria - (08/07/23)
   
  
More Hep C Articles...
 

• HBV Patient Declaration of Rights -
   
  
• Brief Report: Hepatitis B Infection or Reactivation After Switch to 2-Drug Antiretroviral Therapy: A Case Series, Literature Review, and Management Discussion - (09/19/23)
   
  
• IAS: Triple Test and Treat for HIV/HBV/HCV-Simple Way to Slow Hep Epidemics? - Mark Mascolini (08/03/23)
   
  
• EASL: A gene editing approach for chronic hepatitis B: elimination of hepatitis B virus in vivo by targeting cccDNA and integrated viral genomes with a sequence-specific ARCUS nuclease - (07/11/23)
   
  
• AASLD: IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) - (07/11/23)
   
  
• Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America - (07/05/23)
   
  
• EASL: Improving hepatitis B screening and linkage to care rates via the electronic medical record, provider engagement, and patient navigation in a large, urban health system - (07/05/23)
   
  
• EASL: Tenofovir prophylaxis during pregnancy for the elimination of mother-to-child transmission of hepatitis B virus: A cost-effectiveness analysis - (07/05/23)
   
  
More Hep B Articles...
 


---


 
Fatty Liver, NAFLD, NASH
 

• IAS: Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis - (08/14/23)
   
  
• IAS: Association between non-alcohol steatohepatitis with significant activity and fibrosis and neurocognitive impairment in people with HIV - (08/02/23)
   
  
• New Name for NAFLD - MASLD - (07/18/23)
   
  
• EASL: Non-alcoholic fatty liver disease awareness, misperception, and their association with healthcare access in Korean general population: a nationally representative survey - (07/11/23)
   
  
• EASL: Non-alcoholic steatohepatitis disease progression in participants from the United States TARGET-NASH real world longitudinal observational study - (07/10/23)
   
  
• EASL: SAFE Score Rates Liver Disease Risk Well in US General Population - Who is SAFE from chronic liver disease? A population-based approach for early detection in the US. - Mark Mascolini (07/05/23)
   
  
• EASL: Significant dose-dependent reduction in liver stiffness using transient elastography in a phase 3 randomized placebo-controlled trial of obeticholic acid over 48 months in patients with pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis - (07/05/23)
   
  
• EASL: A global research priority agenda to advance public health responses to fatty liver disease - (07/05/23)
   
  
More Fatty Liver Articles...
 

List not necessarily listed here in order of date being held.